Amylyx Pharmaceuticals reports Q3 loss, strong cash position and plans FDA filing for avexitide
Amylyx Pharmaceuticals posted a net loss of $45.49 million for the third quarter of 2026, with revenue of about $69,000. Operating expenses rose to $49.7 million, driven by $28.4 million in research and development spending. The company said its Phase III LUCIDITY trial showed a 55 % cut in hypoglycemic events and that it remains on track to submit an NDA for avexitide by the end of 2026, targeting a 2027 launch for post‑bariatric hypoglycemia. A recent $545 million equity raise left the balance sheet with $768 million of cash.
Why it matters
The loss underscores the company’s continued reliance on financing, but the sizable cash balance gives it runway into 2028. Management’s statement that the NDA will be filed by year‑end signals a potential regulatory milestone that could unlock commercial revenue in 2027.
Key facts
- 1Net loss for Q3 2026 was $45.49 million. tradingview.com
- 2Revenue for the quarter was roughly $69,000. investing.com
- 3Operating expenses increased 38 % to $49.7 million. finance.yahoo.com
- 4Research and development costs were $28.4 million, up 43 % year‑over‑year. finance.yahoo.com
- 5The LUCIDITY Phase III trial achieved a 55 % reduction in hypoglycemic events versus placebo. finance.yahoo.com
- 6Amylyx plans to submit an NDA for avexitide to the FDA by the end of 2026. finance.yahoo.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.